Health-related quality of life, somatosensory amplification, and perceived stress in autosomal dominant polycystic kidney disease: An observational study

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development of fluid-filled cysts in the kidneys, which can lead to the gradual loss of kidney function over time. This study aimed to explore the health-related quality of life (HRQOL), levels of somatosensory amplification, and perceived stress in patients with ADPKD. A total of 48 patients with ADPKD and 50 healthy volunteers aged 18 and older participated in this study. All patients participating in the study were assessed using the 12-item Short Form Healthy Survey version 2, the Somatosensory Amplification Scale (SSAS), and the Perceived Stress Scale (PSS). The scores of the SSAS and the PSS for the patient group were higher but the HRQOL score was lower than those for the healthy group. Upon a simple linear regression analysis, the effect of duration of disease in the polycystic kidney disease (PKD) group on HRQOL was 13.4% and the effect of level of perceived stress on the somatosensory amplification was 18.4%. The patients in the PKD group exhibited higher levels of somatosensory amplification and level of perceived stress but lower levels of HRQOL than the healthy group. The patients with ADPKD experience significantly higher levels of somatosensory amplification and perceived stress, along with lower HRQOL, compared to healthy individuals. The findings highlight the negative psychosocial burden associated with ADPKD, with disease duration affecting HRQOL and perceived stress influencing somatosensory amplification.

Keywords

Polycystic kidney / Stress / Somatosensory amplification / Health-related quality of life

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006; 1(1):148-157. doi: 10.2215/CJN.00330705

[2] Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int. 2001; 60(5):1631-1644. doi: 10.1046/j.1523-1755.2001.00985.x

[3] Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Turk Klin J Nephrol Spec Top. 2012; 5:43-49.

[4] McKercher CM, Venn AJ, Blizzard L, et al. Psychosocial factors in adults with chronic kidney disease: Characteristics of pilot participants in the Tasmanian Chronic Kidney Disease study. BMC Nephrol. 2013; 14:83. doi: 10.1186/1471-2369-14-83

[5] Pérez Domínguez TS, Rodríguez Pérez A, Buset Ríos N, et al. Psychonephrology: psychological aspects in autosomal dominant polycystic kidney disease. Nefrologia. 2011; 31(6):716-722. doi: 10.3265/Nefrologia.pre2011.Jul.10847

[6] Pötzl L, Wolf OT, Merz CJ. Rapid and delayed stress effects on recognition of female and male faces. Psychoneuroendocrinology. 2023; 150:106043. doi: 10.1016/j.psyneuen.2023.106043

[7] Böell JE, Silva DM, Hegadoren KM. Sociodemographic factors and health conditions associated with the resilience of people with chronic diseases: A cross sectional study. Rev Lat Am Enfermagem. 2016; 24:e2786. doi: 10.1590/1518-8345.1205.2786

[8] Yazar C, Ensarioglu M, Cekmen N. Massive liver and kidney cysts excision: A case report. Clin Med Rev Case Rep. 2022; 9:414. doi: 10.23937/2378-3656/1410414

[9] De Rechter S, Bammens B, Schaefer F, Liebau MC, Mekahli D. Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: The paediatric perspective. Clin Kidney J. 2018; 11(Suppl 1):i14-i26. doi: 10.1093/ckj/sfy088

[10] Pascoe MC, Thompson DR, Castle DJ, McEvedy SM, Ski CF. Psychosocial interventions for depressive and anxiety symptoms in individuals with chronic kidney disease: Systematic review and meta-analysis. Front Psychol. 2017; 8:992. doi: 10.3389/fpsyg.2017.00992

[11] Lee YJ, Kim MS, Cho S, Kim SR. Association of depression and anxiety with reduced quality of life in patients with predialysis chronic kidney disease. Int J Clin Pract. 2013; 67(4):363-368. doi: 10.1111/ijcp.12020

[12] Kandemir I, Gudek K, Sahin AY, et al. Association of problems, coping styles, and preferred online activity with depression, anxiety, and other psychological disorders in Turkish adolescents diagnosed with chronic kidney disease. Pediatr Nephrol. 2024; 39(9):2779-2788. doi: 10.1007/s00467-024-06391-9

[13] Ozcan H, Yucel A, Avşar UZ, et al. Kidney transplantation is superior to hemodialysis and peritoneal dialysis in terms of cognitive function, anxiety, and depression symptoms in chronic kidney disease. Transplant Proc. 2015; 47(5):1348-1351. doi: 10.1016/j.transproceed.2015.04.032

[14] Moreira JM, Bouissou Morais Soares CM, Teixeira AL, Simões E Silva AC, Kummer AM. Anxiety, depression, resilience and quality of life in children and adolescents with pre-dialysis chronic kidney disease. Pediatr Nephrol. 2015; 30(12):2153-2162. doi: 10.1007/s00467-015-3159-6

[15] Laube NF, Mader L, Heinzelmann MA, et al. Psychological distress in adults after pediatric kidney replacement therapy. Pediatr Nephrol. 2024. doi: 10.1007/s00467-024-06571-7

[16] Alavi NM, Aliakbarzadeh Z, Sharifi K. Depression, anxiety, activities of daily living, and quality of life scores in patients undergoing renal replacement therapies. Transplant Proc. 2009; 41(9):3693-3696. doi: 10.1016/j.transproceed.2009.06.217

[17] Li C, Mao W, Liu X. Depression, anxiety and reduced quality of life in predialysis: Differences across the CKD stages? Int J Clin Pract. 2014; 68(5):657-658. doi: 10.1111/ijcp.12422

[18] Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10(9):895-926. doi: 10.1016/j.jpain.2009.06.012

[19] Ferentzi E, Köteles F, Csala B, et al. What makes sense in our body? Personality and sensory correlates of body awareness and somatosensory amplification. Pers Individ Dif. 2017; 104:75-81. doi: 10.1016/j.paid.2016.07.034

[20] Keskin ET, Bozkurt M, Özdemir H, et al. The severity of renal colic pain: Can it be predicted? Can Urol Assoc J. 2023; 17(9):E257-E262. doi: 10.5489/cuaj.8283

[21] Kivrak Y, Kose-Ozlece H, Ustundag MF, Asoglu M. Pain perception: Predictive value of sex, depression, anxiety, somatosensory amplification, obesity, and age. Neuropsychiatr Dis Treat. 2016; 12:1913-1918. doi: 10.2147/NDT.S106974

[22] Iliuta IA, Kalatharan V, Wang K, et al. Polycystic kidney disease without an apparent family history. J Am Soc Nephrol. 2017; 28(9):2768-2776. doi: 10.1681/ASN.2016090938

[23] Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367(25):2407-2418. doi: 10.1056/NEJMoa1205511

[24] Schneiderman N, Ironson G, Siegel SD. Stress and health: Psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2005; 1:607-628. doi: 10.1146/annurev.clinpsy.1.102803.144141

[25] Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009; 60:321-337. doi: 10.1146/annurev.med.60.101707.125712

[26] Widjast EP, Halim MS. Personality, coping strategy, and quality of life of patients with chronic kidney disease. J Psikol. 2021; 48(3):199-213. doi: 10.22146/jpsi.37875

[27] Prihodova L, Nagyova I, Rosenberger J, Roland R, Van Dijk JP, Groothoff JW. Impact of personality and psychological distress on health-related quality of life in kidney transplant recipients. Transpl Int. 2010; 23(5):484-492. doi: 10.1111/j.1432-2277.2009.01003.x

[28] Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ. Prevalence of major depressive episode in CKD. Am J Kidney Dis. 2009; 54(3):424-432. doi: 10.1053/j.ajkd.2009.03.017

[29] Duarte PS, Miyazaki MC, Blay SL, Sesso R. Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Kidney Int. 2009; 76(4):414-421. doi: 10.1038/ki.2009.156

[30] Ware J Jr., Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-233. doi: 10.1097/00005650-199603000-00003

[31] Koçyiğit H, Aydemir Ö, Ölmez N, Memiş A. Reliability and validity of the SF-36 for the Turkish population. Ege Fizik Tedavi Rehabilitasyon Derg. 1999; 12:102-106. [In Turkish].

[32] Barsky AJ, Wyshak G, Klerman GL. The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatr Res. 1990; 24(4):323-334. doi: 10.1016/0022-3956(90)90004-a

[33] Güleç H, Sayar K. Reliability and validity of the Turkish form of the somatosensory amplification scale. Psychiatry Clin Neurosci. 2007; 61(1):25-30. doi: 10.1111/j.1440-1819.2007.01606.x

[34] Eskin M, Harlak H, Demirkıran F, Dereboy Ç. Adaptation of the perceived stress scale into Turkish: Reliability and validity analysis. J New Symp. 2013; 51(3):132-140. [In Turkish].

[35] Ma LC, Chang HJ, Liu YM, et al. The relationship between health-promoting behaviors and resilience in patients with chronic kidney disease. ScientificWorldJournal. 2013; 2013:124973. doi: 10.1155/2013/124973

[36] Mapes DL, Lopes AA, Satayathum S, et al. Health-related quality of life as a predictor of mortality and hospitalization: The dialysis outcomes and practice patterns study (DOPPS). Kidney Int. 2003; 64(1):339-349. doi: 10.1046/j.1523-1755.2003.00072.x

[37] Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: Early occurrence and unique aspects. J Am Soc Nephrol. 2001; 12(1):194-200. doi: 10.1681/ASN.V121194

[38] Cohen D, Timsit MO, Chrétien Y, et al. Place de la néphrectomie chez les patients atteints de polykystose rénale autosomique dominante de l’adulte en attente de transplantation rénale [Place of nephrectomy in patients with autosomal dominant polycystic kidney disease waiting for renal transplantation]. Prog Urol. 2008; 18(10):642-649. doi: 10.1016/j.purol.2008.06.004

[39] Hoover E, Holliday V, Merullo N, et al. Pain and health-related quality of life in autosomal dominant polycystic kidney disease: Results from a national patient-powered registry. Kidney Med. 2024; 6(5):100813. doi: 10.1016/j.xkme.2024.100813

[40] Rizk D, Jurkovitz C, Veledar E, et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009; 4(3):560-566. doi: 10.2215/CJN.02410508

[41] Untas A, Thumma J, Rascle N, et al. The associations of social support and other psychosocial factors with mortality and quality of life in the dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol. 2011; 6(1):142-152. doi: 10.2215/CJN.02340310

[42] Palmer S, Vecchio M, Craig JC, et al. Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies. Kidney Int. 2013; 84(1):179-191. doi: 10.1038/ki.2013.77